Palmitoylethanolamide for Chronic Inflammatory Pain Conditions

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Chronic Pain

In brief

The goal of this clinical trial is to evaluate if a supplement called palmitoylethanolamide (PEA) is effective in reducing the pain in patients with chronic inflammatory pain conditions. The main question the trial aims to answer is if PEA works better at treating a patients pain and improving their function better than a placebo. Participants will be divided into two equal groups and asked to take either PEA or a placebo for 8 weeks.

Key facts

Study ID

NCT06273462

Run by

Navy Medical Center San Diego

People needed

80

Starts

2024-08-05

Expected to finish

2025-10-30

Last updated by the study team

2024-08-15

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Chronic Inflammatory Pain of greater than 3 months duration and greater than or equal to 5/10 intensity that has not responded to other conservative therapies such as rest, ice, compression or other oral medications.

You may not qualify if…

• Severe allergy to any specific food component such as nut, egg or soy

Where it is running

• Naval Medical Center San Diego — San Diego, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.